- IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www-micromedexsolutions-com.libproxy.uthscsa.edu/ (cited: March 9, 2022).
- Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2022. Available at: http://www.clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed March 9, 2022.
- Berotralstat oral capsules (Orladeyo®) package insert. BioCryst Pharmaceuticals, Inc., December 2020.
- C1 esterase inhibitor, human (Berinert®) package insert. CSL Behring, September 2021.
- C1 esterase inhibitor, human intravenous injection (Cinryze®) package insert. ViroPharma Biologics LLC, January 2021.
- C1 esterase inhibitor subcutaneous injection (Haegarda®) package insert. CSL Behring, October 2020.
- C1 esterase inhibitor, recombinant (Ruconest®) package insert. Pharming Healthcare Inc., April 2020.
- Ecallantide subcutaneous injection (Kalbitor®) package insert. Takeda Pharmaceuticals America, Inc., November 2021.
- Eculizumab intravenous injection (Soliris®) package insert. Alexion Pharmaceuticals, Inc., April 2021.
- Icatibant subcutaneous injection (Firazyr®) package insert. Takeda Pharmaceuticals America, Inc., September 2020.
- Icatibant subcutaneous injection (Sajazir®) package insert. Cycle Pharmaceuticals LTD., June 2021.
- Lanadelumab subcutaneous injection (Takhzyro®) package insert. Takeda Pharmaceuticals America, Inc., February 2022.
- Pegcetacoplan subcutaneous solution (Empaveli®) package insert. Apellis Pharmaceuticals, Inc., August 2021.
- Ravulizumab intravenous injection (Ultomiris®) package insert. Alexion Pharmaceuticals, Inc., January 2022.
- Agalsidase beta injection (Fabrazyme®) package insert. Genzyme Corporation, August 2021.
- Alglucosidase alfa injection (Lumizyme®) package insert. Genzyme Corporation, July 2021.
- Avalglucosidase alfa intravenous injection (Nexviazyme®) package insert. Genzyme Corporation, August 2021.
- Elapegademase intramuscular injection (Revcovi®) package insert. Leadiant Biosciences, November 2021.
- Elosulfase injection (Vimizim®) package insert. BioMarin Pharmaceutical Inc., January 2021.
- Galsulfase injection (Naglazyme®) package insert. BioMarin Pharmaceutical Inc., April 2020.
- Idursulfase injection (Elaprase®) package insert. Shire Human Genetic Therapies, Inc., October 2021.
- Imiglucerase injection (Cerezyme®) package insert. Genzyme Corporation, January 2022.
- Laronidase intravenous infusion (Aldurazyme®) package insert. Genzyme Corporation, December 2019.
- Migalastat oral capsules (Galafold®) package insert. Amicus Therapeutics US, LLC, December 2021.
- Sacrosidase oral solution (Sucraid®) package insert. QOL Medical, LLC, August 2021.
- Sebelipase injection (Kanuma®) package insert. Alexion Pharmaceuticals, Inc., November 2021.
- Taliglucerase alfa injection (Elelyso®) package insert. Pfizer, July 2021.
- Velaglucerase alfa injection (Vpriv®) package insert. Takeda Pharmaceuticals America, Inc., October 2021.
- Vestronidase alfa-vjbk injection (Mepsevii®) package insert. Ultragenyx Pharmaceutical Inc., December 2020.
- Protein C concentrate (Ceprotin®) package insert. Baxalta US Inc., September 2021.
- Asfotase alfa injection (Strensiq®) package insert. Alexion Pharmaceuticals, Inc., April 2021.
- Cerliponase alfa injection (Brineura®) package insert. BioMarin Pharmaceutical Inc., July 2020.
- Ramaswami U, Parini R, Kampmann C, Beck M. Safety of agalsidase alfa in patients with Fabry disease under 7 years. Acta Paediatrica. 2011;100(4):605-11.